Key Details
Price
$0.74Last Dividend
$73.13Annual ROE
-97.94%Beta
2.05Events Calendar
Next earnings date:
Mar 14, 2025Recent quarterly earnings:
Nov 13, 2024Recent annual earnings:
Mar 14, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
Nov 9, 2012Next split:
N/ARecent split:
Feb 14, 2018Analyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Events
Dividend per share
Dividend yield
Other
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
Independent Data Safety Monitoring Board (DSMB) recommends study to proceed without modifications based on initial safety assessment of 400 participant 30-day data
VAXART, INC. (VXRT) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.10.
Vaxart, Inc. (NASDAQ:VXRT ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Edward Berg - Senior Vice President and General Counsel Steven Lo - Chief Executive Officer James Cummings - Chief Medical Officer Sean Tucker - Senior Vice President and Chief Scientific Officer Phillip Lee - Chief Financial Officer Conference Call Participants Cheng Li - Oppenheimer Mayank Mamtani - B. Riley Securities Liang Cheng - Jefferies Operator Greetings and welcome to the Vaxart Business Update and Third Quarter 2024 Financial Results Conference Call.
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that on August 26, 2024, the Compensation Committee of the Board of Directors granted inducement equity awards covering an aggregate of 32,250 shares of its common stock to two new non-executive employees to induce them to accept employment with Vaxart.
Oppenheimer initiated coverage on Vaxart Inc. VXRT, an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines.
VAXART, INC. (VXRT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of $0.03.
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif.
— Cash runway extended into 2026 — — Received one of the largest BARDA-funded Project NextGen Awards to date, up to $453 million — — Company well-capitalized to execute on multiple key clinical and regulatory milestones in COVID-19 and norovirus programs — SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today provided business and cash runway updates as the Company continues to advance its oral pill vaccine platform.
SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart”) (Nasdaq: VXRT) today announced an underwritten offering of 50,000,000 shares of its common stock at an offering price of $0.80 per share, which is a premium to the last closing price of $0.75 per share. Gross proceeds to Vaxart from the offering are expected to be $40 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Vaxart. The offering is expected to close on or about June 17, 2024, subject to customary closing conditions.
— 10,000-subject Phase 2b study will evaluate Vaxart's next generation oral pill COVID-19 vaccine against an approved mRNA vaccine comparator —
FAQ
- What is the ticker symbol for Vaxart?
- Does Vaxart pay dividends?
- What sector is Vaxart in?
- What industry is Vaxart in?
- What country is Vaxart based in?
- When did Vaxart go public?
- Is Vaxart in the S&P 500?
- Is Vaxart in the NASDAQ 100?
- Is Vaxart in the Dow Jones?
- When was Vaxart's last earnings report?
- When does Vaxart report earnings?
- Should I buy Vaxart stock now?